You are here

Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)

Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes

New Orleans, US, 13 June 2016 - New phase 3a findings showed that faster-acting insulin aspart demonstrated a statistically significant reduction in HbA1c in type 1 diabetes, compared with NovoRapid® (insulin aspart)1, a comparable HbA1c reduction in type 2 diabetes versus NovoRapid®2 and improved post-meal or postprandial glucose (PPG) control in type 1 and type 2 diabetes1,2. Results from the onset 1 and onset 2 treat-to-target trials comparing faster-acting insulin aspart with NovoRapid® were presented at the 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, US. 

Read the full release including references

Further information

 

Media:    
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Åsa Josefsson +45 3079 7708 aajf@novonordisk.com
 

Investors:
   
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Attachment

Sunday, November 4, 2018 - 18:30